Sign In
Buy CDNA
$22.31
+0.240 (+1.09%)
At Close: Jun 03, 2026
CareDx Launches ACROBAT Study to Potentially Change Care Paradigm for Stem Cell Transplant Patients
07:00am, Monday, 26'th Jul 2021
ACROBAT is the prospective multi-center study of AlloHeme, to study the potential of relapse surveillance for stem cell transplant patients ACROBAT is the prospective multi-center study of AlloHeme, t
Apple, Array Tech, Vertex Pharma and More Tuesday Afternoon Analyst Calls
12:32pm, Tuesday, 20'th Jul 2021
With the trading day more than halfway over, the broad markets were rallying after the carnage on Monday.
CareDx to Report Second Quarter 2021 Financial Results
07:00am, Thursday, 15'th Jul 2021
SOUTH SAN FRANCISCO, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinic
CareDx Transplant Patient App, AlloCare, Expands Access to the Majority of Transplant Patients
04:01pm, Thursday, 01'st Jul 2021
AlloCare launches in Android Play Store, and is now available on both iOS and Android for all transplant patients AlloCare launches in Android Play Store, and is now available on both iOS and Android
CareDx to Participate in Raymond James 2021 Human Health Innovation Conference
07:00am, Wednesday, 16'th Jun 2021
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinica
CareDx congratulates Hannah Valantine for her State of the Art Lecture at ATC on Transplant Equity
07:00am, Wednesday, 09'th Jun 2021
Valantine's ATC Presentation Highlights the Role of AlloMap and AlloSure on Inclusive Research and Development Valantine's ATC Presentation Highlights the Role of AlloMap and AlloSure on Inclusive Res
KOAR is the largest prospective validation study on AlloSure surveillance with over 1,500 patients enrolled KOAR is the largest prospective validation study on AlloSure surveillance with over 1,500 pa
CareDx Presents Groundbreaking AlloSure® Data at the 2021 American Transplant Congress
07:00am, Friday, 04'th Jun 2021
Transplant physicians to present 40 scientific abstracts, plus two symposia to highlight latest data from multi-center studies on clinical utility of AlloSure Transplant physicians to present 40 scien
CareDx Advances Artificial Intelligence in Transplantation
04:05pm, Thursday, 03'rd Jun 2021
Partnership with OrganX to develop decision support systems Partnership with OrganX to develop decision support systems
APA, Bloom Energy, NetApp and More Thursday Afternoon Analyst Calls
11:50am, Thursday, 03'rd Jun 2021
With the trading day about halfway over, the markets were sliding, with the tech sector getting the worst of it.
CareDx Starts Enrollment in MAPLE, a Multi-modal, Multi-center, Prospective Study of LiverCare
08:09am, Tuesday, 01'st Jun 2021
Study to demonstrate utility of LiverCare post-transplant surveillance for liver transplant recipients Study to demonstrate utility of LiverCare post-transplant surveillance for liver transplant recip
CareDx Announces Strategic Minority Investment in Miromatrix
06:00pm, Friday, 28'th May 2021
Participation in Series C and Research Partnership to Advance Development of Bioengineered Transplantable Organs Participation in Series C and Research Partnership to Advance Development of Bioenginee
CareDx: The Market Leader In Organ Transplant Diagnostic Solutions/Software, With Strong Growth Prospects
03:58pm, Monday, 24'th May 2021
CareDx, Inc (CDNA) is dominating the organ transplant diagnostic solutions market, growing at 40% annually.
CareDx to Participate in AAKP and George Washington University Global Summit on Kidney Disease Innovations
07:00am, Thursday, 13'th May 2021
CareDx to share innovations in donor-derived cell-free DNA (dd-cfDNA) and patient engagement CareDx to share innovations in donor-derived cell-free DNA (dd-cfDNA) and patient engagement
This Under-the-Radar Healthcare Company Quietly Surged During the Pandemic
10:15am, Friday, 07'th May 2021
CareDx just posted 76% year-over-year revenue growth for the first quarter and raised its 2021 guidance.
